Video

Pathophysiology of AD Treatments

Author(s):

Andrew Blauvelt, MD

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

Related Videos
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Related Content
Study Finds Nemolizumab Significantly Improved Signs, Symptoms in Prurigo Nodularis
December 5th 2024

Study Finds Nemolizumab Significantly Improved Signs, Symptoms in Prurigo Nodularis

Tim Smith
The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD
November 18th 2024

The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD

Mona Shahriari, MD, FAAD Linda Stein Gold, MD Susan Taylor, MD
This Year in Medicine 2024: Stories that Defined Healthcare
December 3rd 2024

This Year in Medicine 2024: Stories that Defined Healthcare

HCPLive Editorial Staff
Default thumbnail for The Medical Sisterhood with Mona Shahriari, MD
October 18th 2024

The Medical Sisterhood: Motherhood in Medicine, with Alexandra Golant, MD

Mona Shahriari, MD, FAAD
FDA Receives sBLA for Guselkumab Treatment of Psoriasis, Juvenile PsA in Adolescents
December 2nd 2024

FDA Receives sBLA for Guselkumab Treatment of Psoriasis, Juvenile PsA in Adolescents

Tim Smith
New Phase 3 Data Suggest Twice-Daily Tofacitinib Etocomil Effective for Atopic Dermatitis
December 2nd 2024

New Phase 3 Data Suggest Twice-Daily Tofacitinib Etocomil Effective for Atopic Dermatitis

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.